Bristol-Myers (BMY), Astra Zeneca (AZN) Report Positive Data for Dapagliflozin in Type 2 Diabetes Trial
Go back to Bristol-Myers (BMY), Astra Zeneca (AZN) Report Positive Data for Dapagliflozin in Type 2 Diabetes Trial| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 3,179,791 | |||||
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 67.01 +1.54 (2.35%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $65.47 | 52 Week High | $77.12 | |||
| Open | $65.79 | 52 Week Low | $49.03 | |||
| Day High | $67.55 | P/E | 43.51 | |||
| Day Low | $65.13 | EPS | $1.54 | |||
| Volume | 7,932,248 | |||||
